Status:
COMPLETED
Memantine in Systemic Lupus Erythematosus
Lead Sponsor:
Johns Hopkins University
Collaborating Sponsors:
Forest Laboratories
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Neuropsychiatric manifestations of Systemic Lupus Erythematosus (NPSLE) are both common and an important source of morbidity. Of the case definitions for NPSLE syndromes that have recently been develo...
Detailed Description
Patients with SLE frequently report cognitive and memory problems and many studies have documented significant cognitive deficits with traditional neuropsychological test batteries. Many traditional n...
Eligibility Criteria
Inclusion
- Clinical diagnosis of SLE
- Self-reported cognitive impairment
Exclusion
- Age \< 18 years.
- History of non-compliance
- Pregnancy
- Liver or renal insufficiency/failure (calculated creatinine clearance \< 50 cc/min)
- Severe SLE flare in the last 6 weeks (defined as SLEDAI \> 12 points)
- Recent (within 4 weeks) change in any medication relevant to cognitive function, including prednisone, anti-depressants, medications for insomnia, narcotic medications, attention deficit disorder medications
- Current alcohol or illicit drug abuse
- Current use of Namenda, Aricept, Provigil
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2007
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT00181298
Start Date
March 1 2006
End Date
May 1 2007
Last Update
March 7 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins Lupus Center, 1830 East Monument Street, Suite 7500
Baltimore, Maryland, United States, 21205